European Organisation for Research and Treatment of Cancer - EORTC
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, European Organisation for Research and Treatment of Cancer - EORTC sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
European Organisation for Research and Treatment of Cancer - EORTC: 15 sponsored US clinical trials, 2 recruiting.
European Organisation for Research and Treatment of Cancer - EORTC sponsors 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 9 completed. 9 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Brain and Central Nervous System Tumors, with 1 trials.
Top-decile sponsor footprint
European Organisation for Research and Treatment of Cancer - EORTC ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
15 total, page 1 of 1
Adjuvant Tebentafusp in High Risk Ocular Melanoma
NCT06246149
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677
Male Breast Cancer: Understanding the Biology for Improved Patient Care
NCT01101425
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
NCT00626990
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
NCT03345095
Diffusion-Weighted MRI for Liver Metastasis
NCT02781935
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
NCT03770468
Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma
NCT01344018
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
NCT01189253
Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor
NCT00047125
Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer
NCT00030511
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
NCT00022191
Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00003279
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
NCT00003805
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
NCT00003031
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 9 |
Therapeutic Areas
Where European Organisation for Research and Treatment of Cancer - EORTC enrollment is open (later-stage tilt)
2 recruiting of 15 indexed (13% open); 9 completed (60%).
Phase mix: 9 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: Brain and Central Nervous System Tumors (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
European Organisation for Research and Treatment of Cancer - EORTC: open-pipeline peers nationwide
Peers matched on 15 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
European Organisation for Research and Treatment of Cancer - EORTC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Dizal Pharmaceuticals · 13% recruiting · 15 trials
- Edgewise Therapeutics · 13% recruiting · 15 trials
- EpicentRx · 13% recruiting · 15 trials
Related
What to do with this European Organisation for Research and Treatment of Cancer - EORTC page
15 registered trials is a research-attention snapshot, not an endorsement of European Organisation for Research and Treatment of Cancer - EORTC or any single study.
- 2 of European Organisation for Research and Treatment of Cancer - EORTC's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Brain and Central Nervous System Tumors is the condition European Organisation for Research and Treatment of Cancer - EORTC studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Brain and Central Nervous System Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
European Organisation for Research and Treatment of Cancer - EORTC pipeline card: 15 registered trials from official public datasets.Report a data error.